Amy Ostrosky
The products from Revere Pharmaceuticals have made a noticeable difference in my health. I'm really happy with the results and will continue using their products.
Ask Trustburn about Revere Pharmaceuticals
AI-generated from reviews on this page. Verify anything important with the company directly.
Michael Desforges
I recently tried a new product and I'm really impressed with the results. It has definitely made a positive difference in my life. Highly recommended!
Vivek Khemka
I've been using Revere Pharmaceuticals products for a while now and I have to say, they never disappoint. The quality is consistently high and their customer service is top-notch.
Pamela Kelley
👍 Revere Pharmaceuticals has been a game-changer for me! Their products have made a significant impact on my health and well-being. I can't recommend them enough. 💯
Patricia Hills
I've been a customer of Revere Pharmaceuticals for a while now and I have to say, their products have changed my life. The quality and effectiveness are unmatched. 👌
Kelli Ryan
🌟 Revere Pharmaceuticals has exceeded my expectations in every way. Their products are amazing and have helped me immensely. I can't thank them enough! 💯
Eric Arnold
I had a great experience with Revere Pharmaceuticals. Their products are of excellent quality and have helped me improve my health. I highly recommend them to anyone in need of pharmaceutical solutions.
Cassidy
I recently tried a new product from this company and I must say, it exceeded my expectations. The results were impressive and I'm very satisfied with the overall experience.
News
No news yet. This is where the business shares its own updates and press.
Photos
No photos yet. Photos shared by reviewers will show up here.
Widgets
Get the widget for your site →About Revere Pharmaceuticals
Revere Pharmaceuticals is an oncology-focused biotechnology company leading the development of small molecule therapeutics targeting Rac1 signaling for cancers with unmet clinical needs. Rac1 activity is a key driver of metastatic progression and drug resistance in diverse cancer types.
Revere’s lead Rac1 targeted drug candidate is REV-440. The successful development of REV-440 has the potential to provide meaningful clinical impact in multiple refractory cancers characterized by aberrant Rac1 signaling. Revere expects REV-440 to enter clinical trials in 2021. Initial clinical development of REV-440 will focus on recurrent ovarian cancer and the critical unmet clinical need of platinum-resistant disease. Treatment of ovarian cancer with REV-440 is supported by compelling preclinical efficacy data.
The company was founded in 2016.
- Website
- reverepharma.com